Prospective observational study to investigate the relationships between pharmacokinetics and therapeutic efficacy of deucravacitinib in patients with psoriasis.

Prospective observational study to investigate the relationships between pharmacokinetics and therapeutic efficacy of deucravacitinib in patients with psoriasis. - Prospective observational study to investigate the relationships between pharmacokinetics and therapeutic efficacy of deucravacitinib in patients with psoriasis.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058737

Enrollment

Registered

2025-08-08

Start date

2024-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who provided a written consent to participate in the study or whose family provided a written consent to participate in the study

Exclusion criteria

Exclusion criteria: 1. Patients with severe infection 2. Patients with active tuberculosis 3. Patients with severe hepatic impairment (Child-Pugh classification of C) 4. Pregnant, breastfeeding or expecting women 5. Others deemed inappropriate by the attending physician

Design outcomes

Primary

Measure	Time frame
To assess the impact of deucravacitinib pharmacokinetics on the therapeutic efficacy.	—

Secondary

Measure	Time frame
To explore factors influencing pharmacokinetics of deucravacitinib	—

Countries

Japan

Contacts

Public ContactTasuku Yokoyama

University of Shizuoka Laboratory of Clinical Pharmaceutics, School of Pharmaceutical Sciences

tyokoyama@u-shizuoka-ken.ac.jp+81-54-264-5857

Outcome results